New Low-DMSO Formula Preserves Stem Cells Better Without Liquid Nitrogen
A novel cryoprotectant using just 2% DMSO matches or outperforms standard methods, simplifying stem cell banking for transplants.
Summary
Researchers developed a new cryoprotective agent (CPA) containing only 2% dimethyl sulfoxide (DMSO) for preserving peripheral blood hematopoietic stem cells (PBHSCs), compared to the standard 10% DMSO solution. Stored at -80°C rather than in liquid nitrogen, the low-DMSO formula matched traditional methods in cell survival (91% vs 90%) while significantly outperforming them in viability (89% vs 80%), cytoskeletal integrity, mitochondrial activity, and colony-forming capacity. This simpler, safer approach could reduce toxicity risks during stem cell infusion in autologous transplant patients, while also lowering logistical burdens associated with liquid nitrogen storage.
Detailed Summary
Autologous stem cell transplantation (ASCT) is a life-saving therapy for blood cancers and other serious conditions, relying on the ability to freeze and rethaw a patient's own stem cells. The standard cryoprotectant — 10% dimethyl sulfoxide (DMSO) — is effective but carries significant toxicity risks when infused into patients, including nausea, cardiovascular effects, and neurological symptoms. Reducing DMSO exposure has been a longstanding clinical goal.
This study, published in the Journal of Visualized Experiments, validated a novel low-DMSO cryoprotective agent (CPA) containing just 2% DMSO for preserving peripheral blood hematopoietic stem cells (PBHSCs). Cells from six donors were cryopreserved using either the new CPA at -80°C or traditional methods (10% DMSO + 5% human albumin) with controlled-rate cooling and liquid nitrogen storage. After one month, cells were thawed and compared across multiple quality metrics.
The low-DMSO CPA performed comparably or better across all measures. Cell survival rates were nearly identical (91.3% vs 90.1%), but viability was meaningfully higher with the new formula (89.4% vs 79.6%, p<0.05). Cytoskeletal structures — both microfilaments and microtubules — were better preserved, and mitochondrial activity in CPA-treated cells closely resembled fresh, never-frozen cells, with 8.5% higher activity than the traditional method. Colony-forming assays, which test functional stem cell capacity, also favored the new CPA.
These results suggest that dramatically reducing DMSO concentration does not compromise, and may actually improve, stem cell quality after cryopreservation. Eliminating liquid nitrogen also simplifies logistics for hospitals and cell therapy centers.
Caveats include the very small donor sample (n=6) and the relatively short storage period tested (one month). Clinical translation will require larger trials and longer-term storage validation.
Key Findings
- Low-DMSO CPA (2%) achieved 91.3% cell survival, matching standard 10% DMSO method at 90.1%.
- Cell viability was significantly higher with CPA (89.4% vs 79.6%, p<0.05).
- Mitochondrial activity in CPA-preserved cells was 8.5% higher than traditional method.
- Cytoskeletal integrity of microfilaments and microtubules was superior with the new CPA.
- CPA enabled -80°C storage, eliminating dependence on liquid nitrogen infrastructure.
Methodology
Six-donor comparative study dividing PBHSCs into two cryopreservation groups: novel 2% DMSO CPA stored at -80°C versus traditional 10% DMSO + 5% albumin with controlled-rate cooling and liquid nitrogen. Cells were thawed after one month and assessed for survival, viability, cytoskeletal integrity, mitochondrial activity, and colony-forming capacity.
Study Limitations
The study included only six donors, making statistical power limited and generalizability uncertain. Storage was evaluated at only one month, leaving long-term stability unconfirmed. Clinical outcomes data from actual transplant recipients are needed before widespread adoption.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.